FEEDS
Agendia Appoints New CEO and Supervisory Board Member
Irvine, California and Amsterdam (ots/PRNewswire) - Agendia, an innovative molecular diagnostics company, today announced that its supervisory board of directors has appointed David Macdonald as chief executive officer. This follows the resignation ... weiter zur Pressemitteilung von Agendia B.V.
EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study
BRUSSELS, IRVINE, California, and AMSTERDAM, October 18, 2011 (ots/PRNewswire) -- The EORTC, BIG, and Agendia, a commercial-stage molecular cancer diagnostics company, today announced the completion of patient registration for the EORTC ... weiter zur Pressemitteilung von Agendia B.V.
Agendia Successfully Completes Bi-Annual FDA Inspection
Irvine, California and Amsterdam (ots/PRNewswire) - Agendia, an innovative molecular cancer diagnostics company, today announced that the company successfully completed a recent, routine inspection of its Irvine, California-based laboratories by the ... weiter zur Pressemitteilung von Agendia B.V.
Breast Cancer Research and Treatment Highlights Development and Validation of BluePrint®
Irvine, California and Amsterdam (ots/PRNewswire) - - Peer-Reviewed Article Notes That Multi-Gene Subtyping Profile Provides Deeper Insight Into Breast Cancer Agendia, an innovative molecular cancer diagnostics company, today announced that a ... weiter zur Pressemitteilung von Agendia B.V.
International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment
Irvine, California and Amsterdam (ots/PRNewswire) - Panel's Recommendations Reinforce Clinical Value of Tests Such as BluePrint(R) Agendia, a commercial-stage molecular cancer diagnostics company, today announced that the 12th St. Gallen ... weiter zur Pressemitteilung von Agendia B.V.
Agendia Receives ?1.27 Million in Funding from the EU's Seventh Framework Programme
Irvine, California and Amsterdam (ots/PRNewswire) - - Company Will Develop Companion Diagnostics With Consortiums of Leading European Cancer Centers and Translational Research Groups Agendia, a global innovator in molecular cancer diagnostics, ... weiter zur Pressemitteilung von Agendia B.V.
Agendia Announces Intention to List on NYSE Euronext in Amsterdam
Amsterdam (ots/PRNewswire) - Agendia (the "Company"), a commercial-stage molecular diagnostic company with operations in the Netherlands and the United States, announces today its intention to raise new funds through an initial public offering ... weiter zur Pressemitteilung von Agendia B.V.
Agendia Announces Colorectal Cancer Collaboration With AstraZeneca and The Netherlands Cancer Institute
Amsterdam and Irvine, California (ots/PRNewswire) - Agendia, an innovative molecular cancer diagnostics company, today announced that it has partnered with AstraZeneca and The Netherlands Cancer Institute (NKI) to accelerate the development of ... weiter zur Pressemitteilung von Agendia B.V.
Agendia Hires David Macdonald as Chief Operating Officer, Mark Willig as Executive VP of North American Sales, and Doug Bradley as Vice President of Global Marketing
Irvine, California and Amsterdam (ots/PRNewswire) - Agendia, a world leader in molecular cancer diagnostics, today announced the hiring of David Macdonald as the company's Chief Operating Officer, Mark Willig as Executive Vice President of North ... weiter zur Pressemitteilung von Agendia B.V.
Agendia Receives Fifth FDA Clearance for Industry Leading MammaPrint(R) Assay
Irvine, California and Amsterdam (ots/PRNewswire) - Agendia, a world leader in molecular cancer diagnostics, today announced that the company has received its fifth U.S. Food and Drug Administration (FDA) clearance for MammaPrint(R), its widely used ... weiter zur Pressemitteilung von Agendia B.V.
Agendia & Collaborators Publish Key MammaPrint Paper in Nature Cell Biology
Irvine, California, and Amsterdam (ots/PRNewswire) - Agendia, a world leader in molecular cancer diagnostics, announced today that together with several groups of scientific collaborators it has identified a major role for TSPYL5, one of its ... weiter zur Pressemitteilung von Agendia B.V.
Agendia Publishes Compelling First Independent Validation Study of Colon Cancer Recurrence Test "ColoPrint" in Journal of Clinical Oncology
Irvine, California and Amsterdam (ots/PRNewswire) - Agendia, a world leader in molecular cancer diagnostics, announced today that together with principal investigators from Spain, the UK, and the Netherlands, it has published the first independent ... weiter zur Pressemitteilung von Agendia B.V.
Agendia Establishes Contract with Humana to Cover MammaPrint
Irvine, California and Amsterdam (ots/PRNewswire) - Agendia, a world leader in molecular cancer diagnostics, announced today that it has established a contract with leading insurance provider Humana to reimburse for the company's MammaPrint test. ... weiter zur Pressemitteilung von Agendia B.V.
Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine
Irvine, California, and Amsterdam, August 5, 2010 (ots/PRNewswire) - Agendia, a world leader in molecular cancer diagnostics, today announced the inauguration of a new state-of-the-art clinical genomics laboratory in Irvine, CA. Previously, ... weiter zur Pressemitteilung von Agendia B.V.
Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests
Irvine, California, and Amsterdam, July 15, 2010 (ots/PRNewswire) - Agendia, a world leader in molecular cancer diagnostics, announced today that company CEO Dr. Bernhard Sixt will provide testimony at a public meeting on July 20 in Washington D.C. ... weiter zur Pressemitteilung von Agendia B.V.
Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
Huntington Beach, California and Amsterdam, June 4, 2010 (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, today announced that researchers from Agendia and leading academic centers in the U.S. and Europe will present data ... weiter zur Pressemitteilung von Agendia B.V.
New Study Demonstrates Patients With High-Risk MammaPrint Profile Benefit From Chemotherapy
HUNTINGTON BEACH, California, and AMSTERDAM, April 29, 2010 (ots/PRNewswire) -- Today, at the 11th Annual Meeting of the American Society of Breast Surgeons, Agendia, a world leader in molecular cancer diagnostics, announced that Breast Cancer ... weiter zur Pressemitteilung von Agendia B.V.
Agendia and Ferrer inCode Expand MammaPrint(R) Distribution Agreement to Latin America
HUNTINGTON BEACH, California and AMSTERDAM, April 20, 2010 (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, announced today it has closed an agreement with Ferrer inCode for the commercialization of Agendia's FDA-cleared ... weiter zur Pressemitteilung von Agendia B.V.
Agendia Launches BluePrint(TM) Expanding Breast Cancer Product Offering
HUNTINGTON BEACH, California and AMSTERDAM, March 24, 2010 (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, today announced that its breast cancer product offering, consisting of breast cancer recurrence test ... weiter zur Pressemitteilung von Agendia B.V.
Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer
HUNTINGTON BEACH, California and AMSTERDAM, March 17, 2010 (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, announced today it will participate in the highly anticipated I-SPY 2 TRIAL for breast cancer, set to launch at ... weiter zur Pressemitteilung von Agendia B.V.
Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
Huntington Beach, California and Amsterdam (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, announced today that it has received the Clinical Laboratory Permit from the New York State Department of Health. The New York ... weiter zur Pressemitteilung von Agendia B.V.
FDA Broadens Clearance for Agendia's MammaPrint(R)
Huntington Beach, California and Amsterdam (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, announced today that the US Food and Drug Administration (FDA) cleared its MammaPrint breast cancer recurrence test for all ages. ... weiter zur Pressemitteilung von Agendia B.V.
Agendia to Present Broad Array of Data at 2009 San Antonio Breast Cancer Symposium
Huntington Beach, California and Amsterdam (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, announced today that it will be presenting six studies focusing on MammaPrint(R) at the 2009 San Antonio Breast Cancer Symposium ... weiter zur Pressemitteilung von Agendia B.V.
Medicare Administrator Establishes Reimbursement Coding Policy for Agendia's Breast Cancer Recurrence Test MammaPrint(R)
Huntington Beach, California and Amsterdam (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, announced today that Palmetto GBA, California's Part B Medicare administrator, has established coding guidelines for the ... weiter zur Pressemitteilung von Agendia B.V.
Agendia schliesst Series-E-Finanzierungsrunde mit 23 Mio. USD ab
HUNTINGTON BEACH, Kalifornien, und AMSTERDAM, September 23 (ots/PRNewswire) -- - Das Unternehmen wird am 23. September auf der UBS Global Life Sciences Conference vortragen Agendia, im Bereich der molekularen Krebsdiagnose weltweit führend, gab ... weiter zur Pressemitteilung von Agendia B.V.
